Is There a Difference in Flicker Induced Vasodilatation Between Smokers and Non-Smokers?
|ClinicalTrials.gov Identifier: NCT00431730|
Recruitment Status : Completed
First Posted : February 6, 2007
Last Update Posted : July 4, 2008
Habitual smoking is associated with an increased risk of coronary artery disease, cerebral and peripheral vascular disease, including ocular diseases like age-related macular degeneration or diabetic retinopathy. Data of a recent study performed in the investigators lab revealed abnormal choroidal blood flow regulation in chronic smokers as compared to age-matched non-smoking subjects during isometric exercise. However, no information is yet available about the regulation of retinal vascular tone in habitual smokers.
Thus, in the current study, the investigators set out to investigate whether the regulation of retinal vessels diameters is affected in habitual smokers. It has been shown in several reports that stimulation with diffuse luminance flicker, increases retinal arterial and venous diameters, indicating for the ability of the retina to adapt to changing metabolic demands. In the current study we use this effect as a tool to investigate whether the flicker induced vasodilatation is affected in habitual smokers. This would indicate for an impaired vascular regulation process in smokers.
|Condition or disease||Intervention/treatment||Phase|
|Ocular Physiology Retina Blood Flow Velocity||Procedure: flicker light stimulation||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Is There a Difference in Flicker Induced Vasodilatation Between Smokers and Non-Smokers?|
|Study Start Date :||December 2006|
|Actual Primary Completion Date :||September 2007|
|Actual Study Completion Date :||September 2007|
- Flicker response (Retinal vessel analyzer, Laser Doppler Velocimetry)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00431730
|Department of Clinical Pharmacology|
|Vienna, Austria, 1090|
|Principal Investigator:||Gabriele Fuchsjaeger-Mayrl, MD||Department of CLinical Pharmacology, Medical University of Vienna|